Zaitceva, V, Tan, I, Mills, M. and Kanavos, P. (2024) HPR253 Drug development and launch timeline analysis across 6 high-income countries: from pivotal trial to HTA. Value in Health, 27 (12, Supplement). S323 - S323. ISSN 1098-3015
Full text not available from this repository.
Identification Number: https://doi.org/10.1016/j.jval.2024.10.1677
Abstract
This study aims to (1) investigate the time intervals between key steps in drug development and launch: pivotal clinical trial, regulatory approval, and HTA decision and (2) explore the impact of drug characteristics, clinical trial design, regulatory pathways, and firm characteristics on these timelines.
| Item Type: | Article |
|---|---|
| Divisions: | Health Policy |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology |
| Date Deposited: | 18 Mar 2025 09:21 |
| Last Modified: | 20 Sep 2025 02:48 |
| URI: | http://eprintstest.lse.ac.uk/id/eprint/127581 |
Actions (login required)
 |
View Item |
